Recipharm Signs Partnership Agreement With Follicum

Recipharm recently announced it has signed a partnership agreement with Follicum AB in preparation for a clinical trial of the drug candidate FOL-005. Recipharm has been engaged to formulate and produce the product that will be used in the clinical trial. The engagement also includes developing and validating the analytical methods required.

“Preparations for the clinical study are well under way, and we have now established ties with partners that we feel confident in. Recipharm is successful in its field and has a strong track record. We look forward to the finished product, which is expected to be ready at the end of the year, in time for the launch of the clinical study,” said Jan Alenfall, CEO of Follicum.

“We have extensive experience in the development of pharmaceuticals for clinical trials and are very excited to be able to contribute to the development of this product,” added Maria Lundberg, General Manager of Recipharm in Solna.

Recipharm is a leading CDMO (Contract Development and Manufacturing Organization) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material, including API and pharmaceutical product development. For more information, visit

Follicum focuses on the development of the pharmaceutical candidate FOL-005, which in preclinical studies has both stimulated and inhibited hair growth effectively even at low doses. The company’s objective is to generate returns and revenues for other future projects by means of a sale or out-licensing of FOL-005 after a successful Phase I/IIa trial. For more information, please visit